一种新型大环内酯类抗生素——醋酸麦迪霉素（美欧卡霉素）的毒理学研究。第四部分 - 12. 美欧卡霉素代谢产物的毒性：Mb12对大鼠的亚急性毒性
Toxicological studies on a new macrolide antibiotic, midecamycin acetate (miocamycin). Part IV-12. Toxicity of metabolites of miocamycin: subacute toxicity of Mb12 in rats.
作者信息
Yokota M, Takeda U, Odaki M, Sasaki H, Niizato T, Kawaoto H, Watanabe H, Ishiwatari N, Hayasaka H, Koeda T
出版信息
Jpn J Antibiot. 1984 Aug;37(8):1552-64.
Miocamycin (MOM) is a derivative of midecamycin and is metabolized into 4 main metabolites of Mb1, Mb2, Mb6 and Mb12. In the previous study, LD0 values of Mb12 in male and female rats were estimated more than 5,000 mg/kg. The object of this study was to evaluate subacute toxicity in male and female rats after repeated oral administration of Mb12 for 5 weeks at a daily dosage of 125, 250, 500 and 1,000 mg/kg. It is concluded that no manifest toxic effects were caused by Mb12 even at the highest dosage level of 1,000 mg/kg/day for 5 weeks to male and female rats.
米卡霉素（MOM）是麦迪霉素的衍生物，可代谢为4种主要代谢物Mb1、Mb2、Mb6和Mb12。在之前的研究中，雄性和雌性大鼠中Mb12的LD0值估计超过5000mg/kg。本研究的目的是评估雄性和雌性大鼠在以每日125、250、500和1000mg/kg的剂量重复口服Mb12 5周后的亚急性毒性。得出的结论是，即使在最高剂量水平1000mg/kg/天持续5周的情况下，Mb12对雄性和雌性大鼠也未造成明显的毒性作用。
Zotero 插件